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Abstract
Amyloid-b-protein (Ab), the key component of senile plaques in Alzheimer’s disease (AD) brain, is produced from
amyloid precursor protein (APP) by cleavage of b-secretase and then g-secretase. APP adaptor proteins with
phosphotyrosine-binding (PTB) domains, including Dab (gene: DAB) and Numb (gene: NUMB), can bind to and
interact with the conserved YENPTY-motif in the APP C-terminus. Here we describe, for the first time, the effects of
RNAi knock-down of Dab and Numb expression on APP processing and Ab production. RNAi knock-down of Dab
and Numb in H4 human neuroglioma cells stably transfected to express either FL-APP (H4-FL-APP cells) or APP-C99
(H4-APP-C99 cells) increased levels of APP-C-terminal fragments (APP-CTFs) and lowered Ab levels in both cell lines
by inhibiting g-secretase cleavage of APP. Finally, RNAi knock-down of APP also reduced levels of Numb in H4-APP
cells. These findings suggest that pharmacologically blocking interaction of APP with Dab and Numb may provide
novel therapeutic strategies of AD. The notion of attenuating g-secretase cleavage of APP via the APP adaptor
proteins, Dab and Numb, is particularly attractive with regard to therapeutic potential, given that side effects of g-
secretase inhibition owing to impaired proteolysis of other g-secretase substrates, e.g. Notch, might be avoided.
Introduction
Amyloid-b-protein (Ab), the key component of senile
plaques in Alzheimer’s disease (AD) neuropathology,
was first isolated from meningovascular amyloid depos-
its in AD and Down’s syndrome [1,2], and has also been
reported to be the subunit of the plaque amyloid [2-4].
The current amyloid hypothesis of AD states that the
imbalance between Ab generation and Ab clearance is
the basis of AD neuropathogenesis. Ab is generated
from amyloid precursor protein (APP). Specifically, APP
is first hydrolyzed by b-secretase to generate a 99-resi-
due membrane-associated C-terminus fragment (APP-
C99) [5-8]. APP-C99 is further cleaved to release a ~4-
kDa peptide, Ab, and the amyloid precursor protein
intracellular domain (AICD). This cleavage is achieved
by an unusual form of proteolysis in which the protein
is cleaved within the transmembrane domain (at residue
+40 or +42) by g-secretase [9-11]. a-secretase cleaves
t h em a j o r i t yo fA P Pi nt h em i d d l eo ft h eA b region of
APP. This cleavage will preclude Ab generation, lead to
the release of a large ectodomain (a-APPs), and leave
behind a carboxy-terminus fragment of 83 amino acids
(APP-C83) in the membrane. g-Secretase cleaves APP-
C83 to produce p3, an amino-terminally truncated form
of Ab [12,13], [see review in [14]].
The cleavage of the APP cytoplasmic tail by g-secre-
tase generates AICD, which contains the strongly con-
served YENPTY-motif. The YENPTY-sequence is a
consensus motif for the binding of adaptor proteins that
possess a phosphotyrosine-binding domain (PTB) pre-
sent in several APP adaptor proteins, such as X11, Fe65,
ShcC, Numb, Dab and JIP families [see review in [15]].
We have previously reported that RNAi knock-down of
X11a, ShcC and Fe65 in H4 human neuroglioma cells
lower Ab levels [16,17].
Dab (encoded by gene DAB), the PTB-containing APP
adaptor protein, can bind to and interact with the
YENPTY-motif of APP [18,19]. Dab has been reported
to function as an adaptor molecule in signal transduc-
tion process [20,21]. Numb (encoded by gene NUMB)i s
known to interact via its PTB domain with APP [22,23].
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Notch, another substrate of g-secretase, can reduce
levels of Numb and Numblike.
To date, the effects of reduced expression of Dab and
Numb on APP processing and Ab production, the key
components of AD neuropathogenesis, have not been
assessed. For this purpose, we established RNAi knock-
down of Dab and Numb in H4 human neuroglioma
cells overexpressing full-length (FL)-APP (H4-FL-APP
cells) and C-99 (H4-APP-C99 cells), and evaluated the
effects of RNAi-mediated knock-down of Dab and
Numb on APP processing and Ab levels.
Experimental procedures
Cell lines
We employed naïve H4 human neuroglioma (H4) cells
and H4 cells stably transfected to express either FL-APP
(H4-FL-APP cells) or APP-C99 (H4-APP-C99 cells).
Peptide APP-C99 is the product of b-secretase, which
therefore contains a-a n dg-, but not b-cleavage sites.
The H4-APP-C99 cells provide a valid system to assess
whether any effects on APP processing are dependent
on g-secretase-mediated APP processing and indepen-
dent of b-secretase-mediated APP processing. All cell
lines were cultured in DMEM (high glucose) containing
9% heat-inactivated fetal calf serum, 100 units/ml peni-
cillin, 100 μg/ml streptomycin, and 2 mM L-glutamine.
Stably transfected H4 cells were additionally supplemen-
ted with 200 μg/ml G418.
RNAi treatment
Small interfering RNA (siRNA) duplex was designed and
obtained from Qiagen against human NUMB,t h eg e n e
encoding Numb (5’- CAGCCTCTTGACCTCGGATAA-
3’). Dab siRNA duplex for DAB, the gene encoding Dab,
was designed and obtained from Dharmacon research,
Inc. (Lafayette, CO 80026) (5’-NNAGGUCAGGAUCG
CAGUGAA-3’). Scrambled siRNA (AATTCTCC
GAACGTGTCACGT) was obtained from Qiagen and
was used as the control siRNA. siRNAs were transfected
into cells by using electroporation (AMAXA, Gaithers-
burg, MD). We mixed 1 million cells, 100 ul AMAXA
electroporation transfection solution and 10 ul 20 uM
siRNA together, then we employed C-9 program in the
AMAXA electroporation device for the cell transfection.
We chose 20 uM siRNA of NUMB and DAB in current
studies because our previous studies have shown that 20
uM siRNA of other APP adaptor protein genes, includ-
ing APBA1 [17], SHC3 [16] and APBB1 [16], can affect
APP processing and reduce Ab levels. The transfected
cells then were placed in one well of a six-well plate
containing 1.5 ml cell culture media. The cells were har-
vested 48 hours after siRNA treatments.
Cell lysis and protein amount quantification
Cell pellets were detergent-extracted on ice using immu-
noprecipitation buffer (10 mM Tris-HCl, pH 7.4, 150
mM NaCl, 2 mM EDTA, 0.5% Nonidet P-40) plus pro-
tease inhibitors (1 μg/ml aprotinin, 1 μg/ml leupeptin, 1
μg/ml pepstatin A). The lysates were collected, centri-
fuged at 12,000 rpm for 10 min, and quantified for total
proteins by the BCA protein assay kit (Pierce, Iselin, NJ).
Western blot analysis of APP processing
Western blot analysis was performed as described by
Xie et al. [25]. Briefly, 40 μg of total protein of each
sample was subjected to SDS-polyacrylamide gel electro-
phoresis using 4-20% gradient Tris/glycine gels under
reducing conditions (Invitrogen, Carlsbad, CA). Next,
proteins were transferred to a polyvinylidene difluoride
membrane (Bio-Rad, Hercules, CA) using a semi-dry
electrotransfer system (Amersham Biosciences, San
Francisco, CA). Nonspecific proteins were blocked using
5% non-fat dry milk in TBST for 1.5 h. Blots were then
incubated with a primary antibody, followed by a sec-
ondary antibody (horseradish peroxidase-conjugated
anti-rabbit antibody 1:10,000; Pierce, New York, NY).
Blots were washed with TBST for 30 min between steps.
Antibody Dab (1:1,000, Novus Biologicals, Littleton, CO)
was used to recognize Dab (35 kDa), antibody Numb
(1:1,000, Abcam, Cambridge, MA) was used to detect
Numb (75 kDa). Antibody A8717 (1:1,000, Sigma, St.
Louis, MO) was used to visualize FL-APP (110 kDa),
APP-C83 (12 kDa) and APP-C99 (10 kDa) in the Wes-
tern blot analysis. The intensity of signals was analyzed
using an image program (NIH Image 1.62). We first
used the levels of b-actin to normalize the levels of
Numb, Dab, FL-APP and APP-CTFs (e.g., determining
the ratio of Numb amount to b-actin amount) to con-
trol for loading differences in total protein amounts. We
then presented the changes in the protein levels of
Numb, Dab, FL-APP, APP-C99 and APP-C83 in the
cells treated with Numb or Dab siRNA as the percen-
tage of those in the cells treated with control siRNA.
Quantitation of Ab using Sandwich ELISA assay
Following the treatment with control siRNA, Numb
siRNA or Dab siRNA, conditioned media was collected,
and secreted Ab was measured with a Sandwich ELISA
a s s a yb yt h eA b ELISA Core Facility at the Center for
Neurological Diseases, Harvard Institute of Medicine,
Harvard Medical School, Boston, Massachusetts, as
described by Xie et al. [16]. Specifically, 96-well plates
were coated with mouse monoclonal antibodies (mAb)
specific to Ab40 (2 G3). Following blocking with Block
Ace, wells were incubated overnight at 4°C with test
samples of conditioned cell culture media, and then an
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dase was added. Plates were then developed with TMB
reagent and well absorbance was measured at 450 nm.
Ab levels in test samples were determined by compari-
son with the signal from unconditioned media spiked
with known quantities of Ab40.
Statistics
ANOVA with repeated measurements was employed to
compare the difference from the control group. P-values
less than 0.05 were considered statistically significant.
Results
RNAi knock-down of Dab increased APP-CTFs levels and
decreased Ab levels in H4-FL-APP cells
We first established conditions under which RNAi
knock-down of Dab significantly reduced protein levels
of Dab in H4-FL-APP cells. The cells were harvested 48
hours after being transfected with either control siRNA
or Dab siRNA, and were subjected to Western blot ana-
lyses in which antibody Dab was used to visualize Dab
levels. Immunoblotting for Dab revealed a visible reduc-
tion in Dab levels following Dab siRNA treatment as
compared to control siRNA treatment (Figure 1A). Dab
siRNA treatment significantly reduced Dab levels by
44% (normalized to b- a c t i n )a sc o m p a r e dt oc o n t r o l
siRNA treatment (Figure 1B, *p < 0.05).
Next, we assessed effects of RNAi-mediated knock-
down of Dab on APP processing in H4-FL-APP cells by
measuring protein levels of FL-APP, APP-C99 and APP-
C83 following Dab or control siRNA treatments. 48
hours after transfection of Dab siRNA or control siRNA,
the cells were harvested and subjected to Western blot
analyses in which antibody A8717 was used to detect
FL-APP, APP-C99 and APP-C83. Immunoblot analysis
of APP-CTFs revealed increases in levels of APP-C99
and APP-C83 in the cells treated with Dab siRNA as
compared to the cells treated with control siRNA
(Figure 1A). Meanwhile, no significant differences in FL-
APP levels were observed between Dab siRNA- and
control siRNA-treated cells. Quantification of FL-APP,
APP-C99 and APP-C83 (normalized to b-actin) revealed
that Dab siRNA treatment led to a 207% increase in
ratio of APP-C99 to FL-APP (Figure 1C, *p < 0.05), and
a similar (176%) increase in ratio of APP-C83 to FL-
APP (Figure 1D, *p < 0.05), as compared to control
Figure 1 Effects of RNAi knock-down of Dab on APP processing and Ab levels in H4-FL-APP cells. In H4-FL-APP cells, Dab siRNA
treatment decreases protein levels of Dab, increases protein levels of APP-C83 and APP-C99, and decreases Ab levels. A. APP processing in
Western blot analyses. Dab immunoblotting shows reductions in protein levels of Dab in the cells treated with Dab siRNA (columns 3 and 4) as
compared to control siRNA (columns 1 and 2). FL-APP immunoblotting reveals that there is no significant difference in the protein levels of FL-
APP in the cells treated with control siRNA or Dab siRNA. APP-CTFs immunoblotting shows increases in protein levels of APP-C99 and APP-C83
in the cells treated with Dab siRNA (columns 3 and 4) as compared to control siRNA (columns 1 and 2). B. Protein levels of Dab assessed by
quantifying Dab in the Western blot. Dab siRNA treatment (black bar) significantly decreases protein levels of Dab as compared to control siRNA
treatment (white bar) (*p < 0.05), normalized to b-actin. C. APP processing assessed by quantifying ratio of APP-C99 to FL-APP in the Western
blot. Dab siRNA treatment (black bar) significantly increases ratio of APP-C99 to FL-APP as compared to control siRNA treatment (white bar) (*p
< 0.05), normalized to b-actin. D. APP processing assessed by quantifying ratio of APP-C83 to FL-APP in the Western blot. Dab siRNA treatment
(black bar) significantly increases ratio of APP-C83 to FL-APP as compared to control siRNA treatment (white bar) (*p < 0.05), normalized to b-
actin. E. Effects of RNAi knock-down of Dab on Ab levels in H4-FL-APP cells. Dab siRNA treatment (black bar) decreases Ab40 levels as compared
to control siRNA treatment (white bar) (*p < 0.05).
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blot representing Dab were obtained from same samples
of the experiments.
Next, we assessed effects of Dab siRNA on Ab levels in
conditioned media. 48 hours after treatment with control
siRNA or Dab siRNA, we measured secreted Ab40 levels
in conditioned cell culture media. Dab siRNA treatment
significantly decreased Ab40 levels as compared to con-
trol siRNA treatment (Figure 1E, *p < 0.05): 34 pg/ml
(Dab siRNA) versus 57 pg/ml (control siRNA). Collec-
tively, these data indicate that RNAi knock-down of Dab
increases levels of APP-C99, APP-C83, and decreases
secreted Ab in H4-FL-APP cells, in a manner similar to
that of g-secretase inhibitor treatment.
RNAi knock-down of Numb increased APP-CTFs levels and
decreased Ab levels in H4-FL-APP cells
We next assessed effects of RNAi knock-down of Numb,
another APP adapter molecule, on APP processing and
Ab levels in H4-FL-APP cells. We first established con-
ditions under which Numb siRNA treatment reduced
protein levels of Numb in H4-FL-APP cells. The cells
were harvested 48 hours after being transfected with
either control siRNA or Numb siRNA, and were sub-
jected to Western blot analyses with Numb antibody to
measure protein levels of Numb. Numb immunoblotting
revealed a 54% reduction in protein levels of Numb fol-
lowing Numb siRNA treatment as compared to control
siRNA treatment (Figure 2A, B, *p < 0.05).
We then assessed effects of RNAi-mediated knock-
down of Numb on APP processing in H4-FL-APP cells
by measuring levels of FL-APP, APP-C99 and APP-C83
following Numb siRNA or control siRNA treatments. 48
hours after transfection of Numb siRNA or control
siRNA, the cells were harvested and subjected to Wes-
tern blot analyses with antibody A8717 to detect FL-
APP, APP-C99, and APP-C83. Levels of APP-C99 and
APP-C83 were increased in the cells treated with Numb
siRNA versus control siRNA( F i g u r e2 A ) .M e a n w h i l e ,
no significant differences in FL-APP levels were
observed for Numb siRNA versus control siRNA-treated
cells (Figure 2A). Numb siRNA treatment led to a 202%
increase in ratio of APP-C99 to FL-APP (Figure 2C,
*p < 0.05), but only a mild (122%) increase in ratio of
APP-C83 to FL-APP (Figure 2D, N.S.), normalized to
b-actin, as compared to control siRNA treatment.
Figure 2 Effects of RNAi knock-down of Numb on APP processing and Ab levels in H4-FL-APP cells.I nH 4 - F L - A P Pc e l l s ,N u m bs i R N A
treatment decreases protein levels of Numb, increases protein levels of APP-C99, and decreases Ab levels. A. APP processing in Western blot
analyses. Numb immunoblotting shows reductions in protein levels of Numb in the cells treated with Numb siRNA (columns 3 and 4) as
compared to control siRNA (columns 1 and 2). FL-APP immunoblotting reveals that there is no significant difference in protein levels of FL-APP
in the cells treated with control siRNA or Numb siRNA. APP-CTFs immunoblotting shows increases in protein levels of APP-C99 in the cells
treated with Numb siRNA (columns 3 and 4) as compared to control siRNA (columns 1 and 2). B. Protein levels of Numb assessed by quantifying
Numb in the Western blot. Numb siRNA treatment (black bar) significantly decreases protein levels of Numb as compared to control siRNA
treatment (white bar) (*p < 0.05), normalized to b-actin. C. APP processing assessed by quantifying ratio of APP-C99 to FL-APP in the Western
blot. Numb siRNA treatment (black bar) significantly increases ratio of APP-C99 to FL-APP as compared to control siRNA treatment (white bar) (*p
< 0.05), normalized to b-actin. D. APP processing assessed by quantifying ratio of APP-C83 to FL-APP in the Western blot. Numb siRNA treatment
(black bar) does not significantly increase ratio of APP-C83 to FL-APP as compared to control siRNA treatment (white bar), normalized to b-actin.
E. Effects of RNAi knock-down of Numb on Ab levels in H4-FL-APP cells. Numb siRNA treatment (black bar) decreases Ab40 levels as compared
to control siRNA treatment (white bar) (*p < 0.05).
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cell culture media. 48 hours after treatment with control
siRNA or Numb siRNA in H4-FL-APP cells, Numb
siRNA decreased Ab40 levels: 34 pg/ml for Numb
siRNA versus 48 pg/ml for control siRNA (Figure 2E,
*p < 0.05). Collectively, these data indicate that RNAi
knock-down of Numb also affects APP processing and
Ab production in a manner similar to that of g-secretase
inhibitor treatment in H4-FL-APP cells.
As discussed in prior section, b-secretase cleaves FL-
APP to produce APP-C99, which can be cleaved by g-
secretase to produce Ab. Therefore, changes in APP
processing and Ab production following treatments of
D a bs i R N Aa n dN u m bs i R N Ac o u l db ed u et oa l t e r a -
tions in either b-secretase or g-secretase activities. In the
following experiments, we set out to determine the
extent to which the alterations in APP processing and
Ab production following RNAi knock-down of Dab or
Numb were independent of b-secretase-mediated APP
processing and dependent on g-secretase-mediated APP
processing, employing H4 cells over-expressing APP-
C99 (H4-APP-C99 cells).
RNAi knock-down of Dab increased APP-CTFs levels and
decreased Ab levels in H4-APP-C99 cells
We employed H4-APP-C99 cells in order to determine
whether RNAi knock-down of Dab-induced alterations
in APP processing and Ab levels were independent of b-
secretase-mediated APP processing. As described in the
prior section, APP-C99 is the product of b-secretase and
harbors a-a n dg-cleavage, but not b-cleavage sites,
therefore H4-APP-C99 cells provide a valid system to
assess whether any effects on APP processing are depen-
dent on g-secretase-mediated APP processing and inde-
pendent of b-secretase-mediated APP processing.
48 hours after transfection of H4-APP-C99 cells with
Dab siRNA or control siRNA, the cells were harvested
and subjected to Western blot analyses in which Dab
antibody was used to detect Dab. Dab immunoblotting
revealed a significant reduction in protein levels of Dab
in the cells treated with Dab siRNA as compared to the
cells treated with control siRNA (Figure 3A). There was
no significant difference in amount of b-actin in control
siRNA- and Dab siRNA-treated cells. Quantification of
Dab in the Western blot, normalized to b-actin, showed
Figure 3 Effects of RNAi knock-down of Dab on APP processing and Ab levels in H4-APP-C99 cells.I nH 4 - A P P - C 9 9c e l l s ,D a bs i R N A
treatment decreases protein levels of Dab, increases protein levels of APP-C83 and APP-C99, and decreases Ab levels. A. APP processing in
Western blot analyses. Dab immunoblotting shows reductions in protein levels of Dab in the cells treated with Dab siRNA (columns 3 to 5) as
compared to the cells treated with control siRNA (columns 1 and 2). APP-CTFs immunoblotting shows increases in protein levels of APP-C99 and
APP-C83 in the cells treated with Dab siRNA (columns 3 to 5) as compared to control siRNA (columns 1 and 2). The blot showing the band of
APP-C83 only is the same blot with less exposure time in developing the film. B. Dab protein levels assessed by quantifying Dab in the Western
blot. Dab siRNA treatment significantly decreases protein levels of Dab as compared to control siRNA treatment (*p < 0.05), normalized to b-
actin. C. APP processing assessed by quantifying ratio of APP-C99 to endogenous FL-APP in the Western blot. Dab siRNA treatment significantly
increases ratio of APP-C99 to FL-APP as compared to control siRNA treatment (*p < 0.05), normalized to b-actin. D. APP processing assessed by
quantifying ratio of APP-C83 to endogenous FL-APP in the Western blot. Dab siRNA treatment significantly increases ratio of APP-C83 to FL-APP
as compared to control siRNA treatment (*p < 0.05), normalized to b-actin. E. Effects of RNAi knock-down of Dab on Ab levels in H4-APP-C99
cells. Dab siRNA treatment decreases Ab40 levels as compared to control siRNA treatment (*p < 0.05).
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protein levels of Dab (Figure 3B, *p < 0.05).
We next assessed effects of RNAi-mediated knock-
down of Dab on APP processing. 48 hours after trans-
fection with Dab siRNA or control siRNA, the cells
were harvested and subjected to Western blot analyses
with antibody A8717. Dab siRNA treatment did not
alter endogenous levels of FL-APP as compared to con-
trol siRNA treatment (data not shown). APP-CTFs
immunoblotting revealed visible increases in protein
levels of both APP-C99 and APP-C83 in the H4-APP-
C99 cells treated with Dab siRNA, compared to control
siRNA (Figure 3A). There was no significant difference
in amount of b-actin in the control siRNA- or Dab
siRNA-treated H4-APP-C99 cells. Quantification of FL-
APP, APP-C99 and APP-C83 revealed that Dab siRNA
treatment led to a 188% increase in ratio of APP-C99 to
FL-APP (Figure 3C, *p < 0.05) and a 199% increase in
ratio of APP-C83 to FL-APP (Figure 3D, *p < 0.05), as
compared to control siRNA treatment.
We then measured secreted Ab levels in conditioned cell
culture media 48 hours after treatment with either control
siRNA or Dab siRNA in H4-APP-C99 cells. Dab siRNA
decreased Ab levels as compared to control siRNA
treatment: 63.5 pg/ml (Dab siRNA treatment), 144.5 pg/
ml (control siRNA treatment) (Figure 3E, *p < 0.05).
These findings suggest that effects of RNAi knock-down
of Dab on APP processing and Ab generation are depen-
dent on g-secretase- and independent of b-secretase-
mediated cleavage of APP.
RNAi knock-down of Numb increased APP-CTFs levels and
decreased Ab levels in H4-APP-C99 cells
Next, we asked whether alterations in APP processing
and Ab levels induced by RNAi knock-down of Numb
were also independent of b-secretase-mediated APP pro-
cessing. For this purpose, we set out to determine effects
of RNAi knock-down of Numb on APP processing and
Ab levels in H4-APP-C99 cells. We first established
RNAi knock-down of Numb in H4-APP-C99 cells by
showing that RNAi knock-down of Numb reduced pro-
tein levels of Numb in H4-APP-C99 cells (Figure 4A, B,
a 46% reduction, *p < 0.05).
We then assessed effects of RNAi knock-down of Numb
on levels of APP-C83, APP-C99 and Ab in H4-APP-C99
cells. 48 hours after transfection with Numb siRNA or
control siRNA, the cells were harvested and subjected to
Western blot analyses with antibody A8717. Numb siRNA
Figure 4 Effects of RNAi knock-down of Numb on APP processing and Ab levels in H4-APP-C99 cells. In H4-APP-C99 cells, Numb siRNA
treatment decreases protein levels of Numb, increases protein levels of APP-C99 and decreases Ab levels. A. APP processing in Western blot
analyses. Numb immunoblotting shows reductions in protein levels of Numb in the cells treated with Numb siRNA (columns 3 and 4) as
compared to control siRNA (columns 1 and 2). APP-CTFs immunoblotting shows increases in protein levels of APP-C99 in the cells treated with
Numb siRNA (columns 3 and 4) as compared to control siRNA (columns 1 and 2). B. Numb protein levels assessed by quantifying Numb in the
Western blot. Numb siRNA treatment significantly decreases protein levels of Numb as compared to control siRNA treatment (*p < 0.05),
normalized to b-actin. C. APP processing assessed by quantifying ratio of APP-C99 to endogenous FL-APP in the Western blot. Numb siRNA
treatment significantly increases ratio of APP-C99 to FL-APP as compared to control siRNA treatment (*p < 0.05), normalized to b-actin. D. APP
processing assessed by quantifying ratio of APP-C83 to endogenous FL-APP in the Western blot. Numb siRNA treatment does not significantly
increase ratio of APP-C83 to FL-APP as compared to control siRNA treatment (*p < 0.05), normalized to b-actin. E. Effects of RNAi knock-down of
Numb on Ab levels in H4-APP-C99 cells. Numb siRNA treatment decreases Ab40 levels as compared to control siRNA treatment (*p < 0.05).
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APP-C83 in H4-APP-C99 cells, without altering endogen-
ous FL-APP levels (data not shown), as compared to con-
trol siRNA treatment (Figure 4A). Quantification of the
Western blot revealed that Numb siRNA treatment led to
a 209% increase in the ratio of APP-C99 to FL-APP
(Figure 4C, *p < 0.05) and only a 130% increase in ratio of
A P P - C 8 3t oF L - A P P( F i g u r e3 D ,N . S . ) ,a sc o m p a r e dt o
control siRNA treatment. Numb siRNA treatment
decreased secreted Ab levels as compared to control
siRNA treatment in H4-APP-C99 cells: 44 pg/ml (Numb
siRNA treatment) versus 68 pg/ml (control siRNA treat-
ment) (Figure 4E, *p < 0.05). These findings suggest that
RNAi knock-down of Numb may affect APP processing
and Ab production at least partially by inhibiting g-secre-
tase-, but not b-secretase-, mediated cleavage of APP, a
manner similar to that of g-secretase inhibitors.
RNAi knock-down of APP decreased Numb levels in H4-
APP cells
A recent study by Chapman et al. [24] showed that high
levels of Notch can decrease Numb and Numblike. Both
APP and Notch are substrates of g-secretase, we
therefore assessed effects of APP on Numb levels in H4-
APP cells. 48 hours after transfection with APP siRNA
or control siRNA, the cells were harvested and subjected
to Western blot analyses with antibodies anti-Numb and
A 8 7 1 7 .W ef i r s ts h o w e dt h a tA P Ps i R N At r e a t m e n t
decreased protein levels of both FL-APP and APP-CTFs
(Figure 5A), suggesting that the APP siRNA treatment
can reduce levels of APP (both FL-APP and APP-CTFs)
in H4-APP cells. Then we were able to show that the
same APP siRNA treatment also reduced levels of
Numb in H4-APP cells (Figure 5A). Quantification of
the Western blot revealed that APP siRNA treatment
led to a 55% (Figure 5B, **p < 0.01), 41% (Figure 5C, **p
< 0.01) and 25% (Figure 5D, **p < 0.01) reduction in
levels of FL-APP, APP-CTFs and Numb, respectively, as
compared to control siRNA treatment. These findings
suggest that RNAi knock-down of APP may affect
Numb metabolism as well.
Control siRNA affected neither APP processing nor Ab
levels in H4-FL-APP or H4-APP-C99 cells
Finally, We found that control siRNA did not affect APP
processing or alter Ab levels as compared to saline
Figure 5 Effects of RNAi knock-down of APP on levels of Numb in H4-APP cells. In H4-APP cells, APP siRNA treatment decreases protein
levels of Numb. A. Levels of FL-APP, APP-CTFs and Numb in Western blot analyses. APP immunoblotting shows reductions in protein levels of
FL-APP, APP-CTFs in the cells treated with APP siRNA (columns 3 and 4) as compared to that treated with control siRNA (columns 1 and 2).
Numb immunoblotting shows reductions in protein levels of Numb in the cells treated with Numb siRNA (columns 3 and 4) as compared to
control siRNA (columns 1 and 2). B. FL-APP levels assessed by quantifying FL-APP in the Western blot. APP siRNA treatment significantly
decreases protein levels of FL-APP as compared to control siRNA (**p < 0.01), normalized to b-actin. C. APP-CTFs levels assessed by quantifying
APP-CTFs in the Western blot. APP siRNA treatment significantly decreases protein levels of APP-CTFs as compared to control siRNA (**p < 0.01),
normalized to b-actin. D. Numb protein levels assessed by quantifying Numb in the Western blot. APP siRNA treatment significantly decreases
protein levels of Numb as compared to control siRNA treatment (*p < 0.05), normalized to b-actin.
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(data not shown). These results confirmed that effects of
RNAi knock-down of Dab or Numb on APP processing
and Ab levels in our experiments were not due to con-
trol siRNA (scrambled siRNA) effects, but owing to
reductions in protein levels of Dab and Numb.
Discussion
Ab accumulation resulting from imbalance between Ab
generation and clearance in brain is a foundation of AD
neuropathogenesis [[1], see review in [26]]. Ab is pro-
duced via serial proteolysis of APP by two proteases, b-
secretase and g-secretase [5-8]. Several APP adaptor
proteins [see review in [15]] have previously been shown
to affect APP processing and Ab production following
overexpression [27-35]. Recent studies showed that
RNAi-mediated knock-down of X11a,S h c C ,F e 6 5a n d
ARH can also affect APP processing and Ab levels
[16,17,36]. However, effects of RNAi knock-down of
other APP adaptor proteins, including Dab and Numb,
on APP processing and Ab production have not been
previously reported. Here, we show for the first time
that RNAi knock-down of Dab and Numb significantly
affects APP processing and Ab levels.
RNAi knock-down of Dab and Numb caused increases
in levels of APP-C99 and APP-C83 in absence of altera-
tions in FL-APP levels, and RNAi for Dab and Numb
decreased secreted Ab levels in H4-FL-APP cells. As
described in prior section, b-secretase and a-secretase
cleaves FL-APP to produce APP-C99 and APP-C83
respectively, then g-secretase cleaves APP-C99 and APP-
C83 to generate Ab and p3 respectively, and AICD.
Therefore, the observed increases in APP-C99 and APP-
C83 levels following Dab or Numb siRNA treatment
could be due either to increases in the activities of b-
secretase and/or a-secretase, or to decreases in g-secre-
tase cleavage of APP-C99 and C83. To distinguish these
two possibilities, we repeated RNAi knock-down of Dab
and Numb experiment in H4 cells over-expressing APP-
C99 (H4-APP-C99 cells), the b-secretase cleavage pro-
duct of APP, and found that Dab or Numb siRNA treat-
ment still increased protein levels of APP-C99 and APP-
C83 and decreased levels of secreted Ab.T h e s ed a t a
indicate that the observed changes in APP processing
and Ab levels following RNAi knock-down of Dab and
Numb are independent of b-secretase-, and most likely
are due to inhibition of g-secretase-mediated cleavage of
APP.
One possible explanation for our current results is
that Dab and Numb, APP adaptor proteins, are essential
for g-secretase cleavage of APP-C99 to generate Ab, per-
haps via facilitating APP trafficking to the sites where g-
secretase can cleave it. Reductions in levels of Dab and
Numb by RNAi knock-down for their encoded genes,
DAB and NUMB, will cause a “break” in APP trafficking
to the sites where g-secretase is located, thereby leading
to the accumulation of APP-CTFs (APP-C99 and APP-
C83), the substrates of g-secretase, and reduction in
levels of Ab, the products of g-secretase. In the future
studies, we will assess effects of over-expression and
reduction of Dab and Numb on APP trafficking to
further test this hypothesis.
To date, many other substrates have been reported to
undergo g-secretase cleavage in addition to APP: Notch,
ErbB-4, E-cadherin, the LDL receptor-related protein
(LRP), CD44 and nectin-1-a [37-43]. All of these sub-
strates are type I membrane proteins residing at or near
cell surface, which undergo ectodomain shedding prior
to g-secretase-like cleavage and release ICDs (intracellu-
lar domains) following proteolysis. In our future
research, we will determine whether or not RNAi
knock-down of Dab and Numb can affect processing of
these other g-secretase substrates. It is also important to
determine the potential interactions between Notch sig-
naling with APP adaptor proteins including Numb, Dab,
X11a, ShcC and Fe65 in our established cellular model.
Taking together, our findings demonstrate, for the first
time, that RNAi-mediated knock-down of Dab and
Numb decrease secretion of Ab, conceivably via inhibit-
ing g-secretase cleavage of APP. These data, together
with those of previous studies, imply that blocking inter-
action of APP with either Dab or Numb, and perhaps
other APP adaptor proteins (e.g., X11a, ShcC and Fe65),
could be a novel therapeutical strategy for treating and/
or preventing AD by lowering Ab accumulation.
Increasing evidence suggest a role of Notch signaling
pathway in neurodegeneration of adult vertebrate ner-
vous system and in AD neuropathogenesis [44,45]. A
recent study showed that overexpressions of APP, APLP1
and APLP2 induce Notch gain-of-function phenotypes in
Drosophila, suggesting a cross-talk between APP family
and Notch [46]. Numb and Dab have been suggested to
be mediators of such APP and Notch interactions [46].
Moreover, it has been suggested that pharmacological
processing of APP in AD treatment may cause alterations
in Notch phenotype through Dab and Numb, thereby
contributing to the side effects of the treatment or even
to increasing risk of AD [46,47]. Therefore, Dab and
Numb could be important targets in the development of
therapeutical strategies for AD. Studies to further identify
the roles of Dab and Numb in AD neuropathogenesis,
including assessment of effects of Dab and Numb on
APP processing, Ab accumulation, synaptic function and
apoptosis, are warranted in the future.
A recent study [24] showed that at low levels of Notch
signaling, Numb and Numblike can negatively regulate
Notch, however, high levels Notch can reduce protein
levels of Numb and Numblike. These findings suggest
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Numb/Numblike. In the present study, we have illu-
strated for the first time that reductions in APP levels
can lead to reductions in Numb levels, and reductions
in Numb levels can lead to reductions in Ab levels. Col-
lectively, these findings suggest that APP (and Ab)a n d
Numb can also have a reciprocal negative regulation,
leading to reductions in Ab levels.
In conclusion, RNAi-mediated knock-down of APP
adaptor proteins, Dab and Numb, attenuate g-secretase-
mediated cleavage of APP, leading to decreased Ab levels.
Our findings, together with those of previous studies, sug-
gest that pharmaceutical modulation of APP adaptor pro-
teins, might potentially serve as a novel therapeutic
approach to treating and preventing AD. The notion of
attenuating g-secretase cleavage of APP via APP adaptor
proteins, such as X11a,S h c C ,F e 6 5 ,D a ba n dN u m b ,i s
particularly attractive, because interactions with these APP
adaptor proteins may bypass unwanted effects of g-secre-
tase inhibition owing to impaired proteolysis of other g-
secretase substrates. More studies are needed to further
investigate these findings and to assess feasibility of such a
therapeutic strategy aimed at lowering Ab levels.
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